Who
Robert B. Bazemore
Director
Company insider
Files Form 4 as: Director, Akari Therapeutics; Director, Ardelyx; Director, Nuvation Bio; President & CEO, Epizyme; Director, Neon Therapeutics; Chief Operating Officer, Synageva Biopharma.
In numbers
- Trades disclosed
- 86
- Buys
- 1
- Sells
- 9
- Bought
- $50K
- Sold
- $984K
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 23 Sep 2014
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $0773 at $0.0004 | filing |
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code M | $13,093 at $0.0004 | filing |
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $12K773 at $16.16 | filing |
| 14 Oct 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $50K3,093 at $16.16 | filing |
| 5 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $37K4,677 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $103K13,100 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —123,397 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —123,397 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —123,731 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $49K123,731 at $0.40 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —30,932 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $12K30,932 at $0.40 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,059 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —41,551 at $0.00 | filing |
News
Critical Review: Nuvation Bio (NYSE:NUVB) vs. OSR (NASDAQ:OSRH)NUVB · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Robert B. Bazemore; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.